⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IPHA News
Innate Pharma S.A. ADS
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
prnewswire.com
IPHA
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
prnewswire.com
IPHA
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
businesswire.com
IPHA
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
businesswire.com
IPHA
Innate Pharma participera à un panel de discussion sur le cancer de la vessie lors de la BTIG Virtual Biotechnology Conference
businesswire.com
IPHA
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
businesswire.com
IPHA
Innate Pharma annonce la finalisation du recrutement de l’escalade de dose dans l’étude de phase 1 évaluant IPH4502, un nouvel anticorps conjugué-médicament (ADC) ciblant la Nectine-4 et utilisant l’exatécan
businesswire.com
IPHA
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
businesswire.com
IPHA
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
prnewswire.com
GTBP
IPHA
INKT
IPSC